Science & Technology-R&D Result

Providing innovative and affordable medicines

for all patients

Zhu, X., Ding, Y., Wang, Q. et al. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. Invest New Drugs (2023). http://doi.org/10.1007/s10637-023-01338-7

Publications

Oral: Binghe Xu, M.D., Ph.D. China-Manufactured Trastuzumab Biosimilar HLX02: Efficacy, Safety and Pharmacokinetics Comparison to Reference TZB in a Phase 3 Metastatic Breast Cancer Study. Award of excellence, Third Prize Winner. [CSCO 2020]
CSCO 2020
Poster: Zhang, J. et al. Efficacy, Safety and Immunogenicity of the Biosimilar HLX03 Compared with Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis: A Randomised, Double-blind, Phase 3 Equivalence Study. [EADV 2020]
EADV 2020
Oral: Shukui Qin, M.D., Ph.D. A Bevacizumab Biosimilar, Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: A Phase 3 Study. Award of excellence, Second Prize Winner. [CSCO 2020]
CSCO 2020
Poster: Qin, S. et al. 104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study. Annals of Oncology, 2020, 31 (suppl_6), S1282. [ESMO Asia 2020]
ESMO Asia 2020
Cai, L., Li, L., Cheng, H. et al. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther (2021). http://doi.org/10.1007/s12325-021-01899-0
Advances in Therapy
Pei-Hua Lin, Chi-Ling Tseng, Yun-Chih Cheng, Chieh-Hsin Ho, Shih Chieh Chen, Yanling Wang, Eugene Liu, Hassan Issafras & Weidong Jiang (2021) Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy, Expert Opinion on Biological Therapy, 21:11, 1491-1507, DOI: 10.1080/14712598.2021.1988072.
Expert Opinion on Biological Therapy

1
...
3
4
5
6
7
8
...
10

Intellectual Property

Relevant Products	Patent Name	Patent Holder	Patent Number	Jurisdiction of Registration	Application Date	Expiry Date	Type
Platform Technology	Kit for detecting DNA residues of CHO cell and using method thereof	Henlius	ZL201110066745.4	Chinese mainland	2011-03-18	2031-03-18	Invention
Platform Technology	Method for detecting DNA content of CHO cells by probe	Henlius	ZL201110099204.1	Chinese mainland	2011-04-20	2031-04-20	Invention
Platform Technology	Eukaryotic expression vector and system for producing recombinant protein by using CHO cells	Henlius	ZL201210211812.1	Chinese mainland	2012-06-25	2032-06-25	Invention
HLX07	Anti-epidermal growth factor receptor (EGFR) antibodies	Henlius	ZL201580029644.6 HK1252789 J/4492 TWI689520 US10584171 AU2015266664 JP6691872 EP3148581 EP3613433 KR102366644 US11261255	Chinese mainland Hong Kong China Macao China Taiwan China The United States Australia Japan UK, GER, FR, ITA, ESP UK, GER, FR, ITA, ESP Korea The United States	2015-05-29	2035-05-29 2035-12-11	Invention
HLX10	Anti-programmed cell death protein 1 monoclonal antibody injection Anti-PD-1 antibodies	Henlius	ZL202010008058.6 HK40018285 ZA201901865 US11028173 RU2752832 JP7072576 ZL201780056868.5 TWI772326 KR102391338 IDP000083833	Chinese mainland Hong Kong China The United States South Africa Russia Japan Chinese mainland Taiwan China Korea Indonesia	2020-01-06 2017-09-09	2040-01-06 2037-09-08 2037-09-09 2037-09-09 2037-09-15 2037-09-09 2037-09-09	Invention
HLX53	AntiI-TIGIT antibodies and methods of use	Henlius	ZL202010024565.9 HK40013828	Chinese mainland Hong Kong China	2020-01-10	2040-01-10	Invention
Platform Technology	Online system for monitoring yield and quality of target protein	Henlius	ZL202020160862.1	Chinese mainland	2020-02-11	2030-02-10	Utility Model
Platform Technology	Online quantitative detection system for target protein	Henlius	ZL202020432845.9	Chinese mainland	2020-03-30	2030-03-29	Utility Model

博亿国际